Tail-End of Swine Flu Helps GlaxoSmithKline Beat Forecasts

Published: Apr 28, 2010

Reuters -- Bumper sales of swine flu vaccine boosted GlaxoSmithKline's first-quarter earnings by 17 percent, more than expected, and the drugmaker reassured investors it could absorb the cost of U.S. healthcare reform.

Back to news